Interestingly, early studies of FGF21 analogs in individuals with T2D found they alleviated dyslipidemia but did not impact glycemic control31, and a new long-acting therapeutic compound, LLF580, was found to lower circulating LDL-C and reduce hepatic fat content in a phase 1 clinical trial of 64 obese adults (clinical trial identifier, NCT03466203) (ref. 65). The gene discussed is FGF21; the disease is metabolic syndrome.